Neogen Corporation (NEOG) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company reported a strong financial performance with a 10% YoY revenue increase, improved gross margins, and a 15% rise in net income. EPS also rose, indicating enhanced profitability. Despite increased operating expenses due to R&D and marketing, the overall financial health appears robust. The raised revenue guidance further supports a positive outlook. However, the lack of details on strategic initiatives and operational updates, along with risks mentioned in forward-looking statements, tempers the sentiment slightly. Given the market cap, a positive stock price movement of 2% to 8% is expected.
Key Financial Performance
Revenue Revenue for Q3 2026 was $250 million, representing a 10% increase year-over-year. This growth was driven by strong performance in the animal safety and genomics segments.
Gross Margin Gross margin improved to 55%, up from 52% in the same quarter last year, due to operational efficiencies and favorable product mix.
Net Income Net income for the quarter was $30 million, a 15% increase compared to Q3 2025, attributed to higher revenues and cost management initiatives.
Operating Expenses Operating expenses were $100 million, up 5% year-over-year, primarily due to increased investment in R&D and marketing.
Earnings Per Share (EPS) EPS for Q3 2026 was $0.25, up from $0.22 in Q3 2025, reflecting improved profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company's forward-looking statements are subject to risks that could cause actual results to differ materially from those expressed or implied. These risks are detailed in the company's most recent annual report on Form 10-K and other filings.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Blair LLC
Brandon Vazquez
CEO President
CFO Senior
CJS Securities
DeBourcy Nephron
Director Riggsbee
Division Brandon
Division Labick
Division Tom
EDT CEO
Inc lady
Instructions Thursday
LLC Research
LLC Westenberg
Neogen Conference
Neogen statement
Piper Sandler
President Director
President Subhalaxmi
Relations Neogen
Research Division
Research LLC
Riggsbee CFO
Sandler Co
Senior Vice
Subhalaxmi Nambi
Tom DeBourcy
Vazquez Blair
Vice President
Westenberg Piper
gentleman Neogen
NEOG Transcript
Neogen Corporation (NEOG) Q3 2026 Earnings Call Transcript
Positive4-9
The company reported a strong financial performance with a 10% YoY revenue increase, improved gross margins, and a 15% rise in net income. EPS also rose, indicating enhanced profitability. Despite increased operating expenses due to R&D and marketing, the overall financial health appears robust. The raised revenue guidance further supports a positive outlook. However, the lack of details on strategic initiatives and operational updates, along with risks mentioned in forward-looking statements, tempers the sentiment slightly. Given the market cap, a positive stock price movement of 2% to 8% is expected.
Neogen Corporation (NEOG) Q2 2026 Earnings Call Transcript
Positive1-8
The earnings call reveals strong financial performance with improved margins and EBITDA, alongside optimistic guidance. The Q&A section highlights effective management and strategic initiatives, such as the Petrifilm manufacturing process and commercial organization changes. Despite some conservative guidance and ongoing challenges, the overall sentiment is positive, with raised guidance and customer confidence in key product lines. Given the market cap, the stock price is likely to react positively, but not overwhelmingly so.
Neogen Corporation (NEOG) Q1 2026 Earnings Call Transcript
Unknown10-9
The earnings call summary presents a mixed picture: while there are positive aspects like the strong performance of Petrifilm and expected EBITDA margin improvement, there are concerns about supply challenges, margin pressures, and a lack of raised guidance despite revenue beats. The Q&A section reveals management's cautious stance, especially regarding early-year uncertainties and execution challenges. These factors, combined with the company's mid-sized market cap, suggest a neutral stock price movement in the short term.
Neogen Corporation (NEOG) Q4 2025 Earnings Call Transcript
Unknown7-29
The earnings call revealed declines in core revenues across segments, a significant goodwill impairment, and a lowered EBITDA. Despite some positive updates, like pathogen testing growth and reduced CapEx, the overall sentiment is negative due to the weak financial performance and market outlook. The Q&A highlighted concerns about tariffs and macroeconomic pressures, further dampening investor sentiment. With a market cap of $3.45 billion, the stock is likely to experience a negative reaction, falling within the -2% to -8% range over the next two weeks.
NEOG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
